The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
The expansion is a natural progression for Upperton who already develops and manufactures small molecule and biological, ...
At a Senate hearing, Kennedy also said the president has directed him to examine the well-established safety of mifepristone, ...
Senators challenged Kennedy, who was nominated as health secretary by President Trump, on his long track record of ...
A short statement from CMS said the agency will consider ways to make Medicare price negotiations, begun under Biden, more ...
States and providers regained access to a key healthcare payments portal late Tuesday amid pushback over the Trump ...
The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...
BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback